Limits...
Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Josefsen LB, Boyle RW - Theranostics (2012)

Bottom Line: Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types.Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms.The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, The University Of Hull, Kingston-Upon-Hull, HU6 7RX, U.K.

ABSTRACT
Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types. Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms. The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.

No MeSH data available.


Related in: MedlinePlus

Clinically Approved Photosensitisers.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3475217&req=5

Figure 12: Clinically Approved Photosensitisers.

Mentions: Second-generation photosensitisers were developed in order to increase the power and efficiency of pdt and broaden the type of diseased tissue that could be treated; research focused on developing agents with higher absorption wavelengths. Increasing the absorption wavelength and having a higher extinction coefficient in the red/near-infrared region of the electromagnetic spectrum (EMS, 600-850nm) allows deeper penetration of illuminating light into the skin, thus increasing the depths at which tumour cells can be targeted. The range of photosensitisers approved for clinical use includes porphyrins, chlorins, texaphyrins, porphycenes, purpurins and phthalocyanines (figures 11 and 12) 2-5, 7, 9, 12, 13, 15, 23, 24, 26, 28-30, 32-34, 43-45, 48-50, 61, 64, 65.


Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Josefsen LB, Boyle RW - Theranostics (2012)

Clinically Approved Photosensitisers.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3475217&req=5

Figure 12: Clinically Approved Photosensitisers.
Mentions: Second-generation photosensitisers were developed in order to increase the power and efficiency of pdt and broaden the type of diseased tissue that could be treated; research focused on developing agents with higher absorption wavelengths. Increasing the absorption wavelength and having a higher extinction coefficient in the red/near-infrared region of the electromagnetic spectrum (EMS, 600-850nm) allows deeper penetration of illuminating light into the skin, thus increasing the depths at which tumour cells can be targeted. The range of photosensitisers approved for clinical use includes porphyrins, chlorins, texaphyrins, porphycenes, purpurins and phthalocyanines (figures 11 and 12) 2-5, 7, 9, 12, 13, 15, 23, 24, 26, 28-30, 32-34, 43-45, 48-50, 61, 64, 65.

Bottom Line: Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types.Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms.The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, The University Of Hull, Kingston-Upon-Hull, HU6 7RX, U.K.

ABSTRACT
Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types. Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms. The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.

No MeSH data available.


Related in: MedlinePlus